Sun Pharma announces regulatory filing of Tildrakizumab in Japan
(01 Aug 2019)
Sun Pharmaceutical Industries announced that one of its wholly owned
subsidiaries has filed an application for Manufacturing and Marketing Authorization of Tildrakizumab
for moderate-to-severe psoriasis and psoriatic arthritis with the Pharmaceuticals and Medical Devices
Agency (PMDA), Japan.